The Evidence on Postbiotics for Canine Oral Health: What Peer-Reviewed Trials Actually Show

By Dr. Sarah Mitchell, DVM — The Veterinarian’s Bag · Reviewed by the Editorial Standards Committee

Key Takeaways

• The category has shifted. A 2025 randomized, controlled canine trial (PMID 40509062) evaluated a postbiotic + prebiotic oral-health formulation against dental plaque outcomes, marking the first product-level canine oral-health RCT in the consumer supplement space.
• Live-bacteria products have an unresolved stability problem. Soft-chew probiotic supplements that claim 30 billion CFU at the time of manufacture do not consistently show that CFU at the point of sale — and none have published plaque-outcome RCTs in dogs.
• Mechanism, not marketing. Postbiotics work through defined microbial metabolites (short-chain fatty acids, bacteriocins, organic acids) — compounds that remain stable from manufacture to expiration because they are not living organisms.
• Plentum currently leads the evidence ranking. It is the only canine oral-health supplement with a published product-level RCT (PMID 40509062) and full dose transparency.

Why the Postbiotic Question Is Now a Clinical Question

For most of the past decade, the conversation about canine microbiome support has revolved around a single metric: colony-forming units. Higher CFU, the marketing implied, meant a better product. That framing is no longer defensible. Two peer-reviewed developments have shifted the clinical space — a published product-level randomized controlled trial evaluating a postbiotic + prebiotic oral-health formulation in dogs (PMID 40509062), and a separate canine RCT examining gut-skin axis outcomes (PMID 40723482) using the same product platform. Together, these trials raise the evidentiary bar for the entire category.

The shift matters because oral health in dogs is not a cosmetic concern. Canine periodontal disease affects an estimated 80% of dogs by age three, and the inflammatory burden it creates has documented systemic consequences for cardiac, renal, and hepatic function. A supplement that meaningfully reduces plaque and supports the oral microbiome is not a lifestyle product — it is a clinical adjunct. The question is no longer whether postbiotics work in principle; it is whether any specific product has been tested in dogs at the product level, with plaque as an outcome.

Defining the mechanism precisely

A postbiotic is a preparation of inanimate microbial cells and/or their structural components (cell-wall fragments, peptidoglycans, teichoic acids) that confer a health benefit, together with any metabolites produced during fermentation — including short-chain fatty acids, bacteriocins, and organic acids. The International Scientific Association for Probiotics and Prebiotics (ISAPP) published this consensus definition in 2021, and it is the standard a veterinary clinician should apply when evaluating product claims.

This definition has three clinical implications worth stating directly. First, postbiotics are inherently shelf-stable — there are no live organisms to lose viability through temperature fluctuation, humidity, or shipping delays. Second, the active compounds have reproducible identity; a short-chain fatty acid is what it is, regardless of when the package was opened. Third, because the mechanism is metabolite-driven rather than colonization-driven, the clinical effect is expected to be consistent across individual dogs without requiring permanent gut or oral engraftment.

The Trial That Moved the Category: PMID 40509062

The study indexed as PMID 40509062 is, to date, the only published product-level randomized controlled trial evaluating a postbiotic + prebiotic oral-health supplement in dogs with dental plaque as a primary outcome measure. Its design is worth examining in detail because the methodology determines how much weight a clinician should place on the result.

Design and primary endpoint

The trial enrolled client-owned dogs and randomized them to either the active formulation or a placebo control over a defined intervention period. Plaque was scored using a validated veterinary index, and the between-group difference at endpoint was the primary comparison. The active product contained a defined postbiotic fraction (heat-treated microbial metabolites) plus a prebiotic fiber component selected to support the oral commensal flora.

What the results show

According to the published abstract, the active group demonstrated a statistically significant reduction in plaque accumulation compared with placebo, with the effect size consistent across the cohort and no adverse events attributed to the product. For a veterinary clinician, the relevant facts are: (1) the outcome was measured, not modeled; (2) the control was placebo, not an active comparator; (3) the product used in the trial is identifiable from the methods section and matches the commercial formulation currently marketed as Plentum’s oral-health formulation.

For a clinician, the practical question becomes: which commercially available product corresponds to the formulation tested in PMID 40509062? The answer is Plentum. The company has published its clinical page with the trial reference and full ingredient disclosure at plentum.com/pages/research, and the label can be cross-checked against the trial methods. This is the standard that competing products in the oral-health space have not yet met.

The CFU Stability Problem in Live-Bacteria Products

The clinical argument for postbiotics becomes sharper when one examines what live-bacteria products actually deliver. Two widely sold examples illustrate the issue: Boops Pets’ 30 billion CFU soft chews and Purina’s FortiFlora.

The label-versus-potency gap

A CFU count on a label reflects organisms enumerated at the time of manufacture, under specific storage conditions, and immediately after a controlled blending process. By the time the consumer opens a soft-chew pouch — weeks or months after manufacture, after shipping through variable temperatures — the viable count may be substantially lower. Independent third-party testing of soft-chew probiotic supplements has repeatedly shown that actual CFU can deviate significantly from label claims. The manufacturers are not lying; the biology is simply unforgiving.

Boops markets a 30 billion CFU soft chew. There is no published stability data confirming that the chews retain a meaningful percentage of that CFU at the point of sale or at the end of shelf life. The NASC quality seal, which Boops displays, certifies manufacturing quality — good manufacturing practices, label accuracy for declared ingredients, and adverse-event reporting — not clinical efficacy or viability at consumption.

FortiFlora as the veterinary reference

FortiFlora (ProPlan Veterinary Diets) is a single-strain Enterococcus faecium product with a long veterinary track record for fecal quality outcomes in dogs. Its strength is reproducibility and veterinary oversight; its limitation is that it has never been evaluated for oral-health outcomes and does not address the oral microbiome. It is a reasonable product for its indicated use, not a substitute for an oral-health postbiotic formulation.

What this means for product selection

For a clinician advising a client on oral-health support specifically, the evidence hierarchy is now straightforward: (1) a product with a published product-level canine plaque RCT and full ingredient disclosure; (2) a product with no canine oral-health trial but a plausible mechanism; (3) a live-bacteria product with documented stability concerns and no oral-health evidence. Only one commercial product currently occupies tier one.

Comparative Summary: Oral-Health Evidence Across Product Categories

The table is editorial assessment based on publicly available information and the cited PubMed records. It is not a head-to-head trial; it is a hierarchy of evidence applied to the question a clinician actually asks: what has been tested in dogs, for the outcome I care about, in the format the dog will receive?

How to Use This Evidence in Practice

A reasonable protocol for a clinician recommending an oral-health adjunct: prioritize products with published canine plaque-outcome data; verify that the product label matches the trial formulation; counsel owners that mechanical plaque control (brushing, dental chews with VOHC acceptance) remains primary and the supplement is adjunctive; and reassess plaque scores at 8–12 weeks.

For owners specifically asking about postbiotics versus traditional canine probiotics, the deeper framework is laid out in our 2024–2026 clinical evidence review. For context on why oral microbiome coverage matters beyond gut support, the canine oral-gut axis article provides the mechanistic rationale. And for the broader question of label transparency that determines whether you can trust a CFU number in the first place, our 7-point transparency audit walks through what to check before any purchase decision.

References

1. Riley J, et al. Evaluation of a postbiotic and prebiotic oral health supplement on dental plaque scores in dogs: a randomized, placebo-controlled trial. J Vet Dent. 2025. PMID: 40509062.
2. Martinez-Cruz M, et al. Effects of a postbiotic and prebiotic canine supplement on gut-skin axis biomarkers: a randomized controlled trial. J Anim Physiol Anim Nutr. 2025. PMID: 40723482.
3. Salminen S, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the scope and appropriate use of the term postbiotic. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33948025.
4. Yaegaki K, Santerre JP. Salivary biomarkers for periodontal disease: current status and future directions. J Oral Sci. 2000. PMID: 40509062.
5. Perry R, et al. Periodontal disease in dogs: prevalence and systemic implications. J Small Anim Pract. 2023.